On
Dial-in number to the teleconference and a conference ID will be received by registering on the link below:
https://conference.financialhearings.com/teleconference/?id=200933
The presentation will also be webcast and can be accessed from the following web address:
https://ir.financialhearings.com/devyser-diagnostics-q2-2023
Speakers: CEO
The information was submitted for publication, through the agency of the contact persons below, on
For more information, please contact:
Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Tel: +46 706 67 3106
E-mail: sabina.berlin@devyser.com
Tel: +46 739 519 502
About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in over 50 countries. Our products are used for advanced genetic testing in the fields of inherited diseases, oncology and transplantation. They provide the opportunity to tailor cancer treatments, diagnose a wide range of genetic diseases and follow up transplant patients. Devyser's products, and unique, patented solution, which require only a single test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time.
Devyser was founded in 2004 and is based in
Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is
For more information, visit www.devyser.com
https://news.cision.com/devyser-diagnostics-ab/r/invitation-to-audiocast-for-devyser-s-q2-report-2023,c3816869
(c) 2023 Cision. All rights reserved., source